Pannek J, Brands F H, Senge T
Urologische Klinik der Ruhr-Universität Bochum, Marienhospital Herne, Herne, Germany.
J Urol. 2001 Oct;166(4):1350-3.
Despite 20 years of experience with injectable bulking agents for stress urinary incontinence results are rather disappointing. The satisfying initial results of collagen injection are rapidly decreasing with time, whereas synthetic bulking agents have shown problems with migration and biocompatibility. The ideal bulking agent would be permanent with a good clinical long-term success rate. We report our experience with Durasphere (Carbon Medical Technologies, Inc., St. Paul, Minnesota), a new injectable bulking agent containing carbon coated beads.
Seven men and 13 women with a mean age of 62.5 years underwent transurethral submucosal injection. The 13 female patients had been diagnosed with type III stress urinary incontinence and each had undergone at least 1 unsuccessful previous operation for urinary incontinence. There were iatrogenic and traumatic sphincter lesions in 6 and 1 of the male patients, respectively. Mean volume injected per treatment was 6.0 cc. Mean followup was 10 months.
After 6 months 76.9% of the female patients were improved but after 12 months the success rate decreased to 33%. In the male patients after 6 months the success rate was 66%, which decreased to 33% after 12 months. At the 6-month followup we observed significant migration of the carbon coated beads into the local and distant lymph nodes as well as into the urethral mucosa.
Due to limited success and proved particle migration, carbon coated beads do not show any improvement over existing bulking materials. The clinical effect of bead migration must be determined before extended use of this substance.
尽管使用注射用填充剂治疗压力性尿失禁已有20年经验,但结果却相当令人失望。胶原蛋白注射最初令人满意的效果会随着时间迅速下降,而合成填充剂则出现了迁移和生物相容性问题。理想的填充剂应是永久性的,且临床长期成功率高。我们报告了使用Durasphere(碳医疗技术公司,明尼苏达州圣保罗)的经验,这是一种新型的含碳包被微珠的注射用填充剂。
13名女性和7名男性,平均年龄62.5岁,接受了经尿道黏膜下注射。13名女性患者被诊断为Ⅲ型压力性尿失禁,且每人此前至少有1次尿失禁手术失败。男性患者中分别有6例医源性括约肌损伤和1例创伤性括约肌损伤。每次治疗平均注射量为6.0立方厘米。平均随访时间为10个月。
6个月后,76.9%的女性患者病情有所改善,但12个月后成功率降至33%。男性患者6个月后的成功率为66%,12个月后降至33%。在6个月的随访中,我们观察到碳包被微珠显著迁移至局部和远处淋巴结以及尿道黏膜。
由于成功率有限且已证实存在颗粒迁移,碳包被微珠并未显示出比现有填充材料有任何改进。在广泛使用该物质之前,必须确定微珠迁移的临床影响。